ERBB2 and cancer: This is not surprising given the different mechanisms of inhibition of ERBB2 signaling and trafficking between cancer cells and cardiomyocytes [40, 41], in which treatment results in reduced proliferation and induction of apoptosis in cancer cell lines [42, 43] and reduced contractility without apoptosis in cardiomyocytes, (Additional file 9: Figure S3) [12, 44].